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While the majority of disease of the mouth is centred upon the direct action of plaque,  the oral tissues can be 
subject to change or damage as a consequence of disease that predominantly affects other body systems. 
Such oral manifestations of systemic disease can be highly variable in both frequency and presentation. As 
lifespan increases and medical care becomes ever more complex and effective it is likely that the numbers of 
individuals with oral manifestations of systemic disease will continue to rise. The present article provides a 
succinct review of oral manifestations of systemic disease.  In view of it being one of a series on Oral Medicine, 
this review focuses upon oral mucosal and salivary gland disorders that may arise as a consequence of 






Disorders of almost any body system can adversely impact upon the mouth. Oral manifestations may be  (1) the 
first, only or most severe feature of systemic disease (2) the principle focus of therapy and/or (3)  the dominant 
cause of a lessening of the affected person’s quality of life. The oral features  that an oral health care provider 
may witness will often be dependent upon the nature of their clinical practice. For example specialists of 
paediatric dentistry and orthodontics are likely to encounter the oral features of patients with congenital disease 
while those specialties allied to disease of adulthood may see manifestations of infectious, immunologically-
mediated or malignant disease.  The present article aims to provide a succinct review of the oral manifestations 
of systemic disease of patients likely to attend oral medicine services. The review will focus upon disorders 
affecting the oral mucosa and salivary glands – as these are tissues of greatest interest to practitioners of Oral 
Medicine. Although systemic disease relevant to Oral Medicine can impact upon the teeth, periodontal tissues 
or cause altered orofacial sensory or motor function these fall out with the scope of the present review.  
 
Oral mucosal manifestations of systemic disease 
The oral mucosa is perhaps the most likely oral tissue to be compromised by acquired systemic disease. The 
following sections will focus upon ulceration and white lesions of the oral mucosa – as these are the most likely 
abnormal signs that will be observed by oral health care providers.   
 
Oral ulceration 
A plethora of local and systemic disorders can give rise to ulceration of the oral mucosa (Table 1).  
 
Solitary ulcers 
Longstanding solitary oral mucosal ulceration should always initially be considered to reflect repeated local 
trauma or malignancy (usually oral squamous cell carcinoma (OSCC; Figure 1)). Of course many other 
disorders that give rise to oral ulceration may initially manifest as single ulcers but over time they evolve into 
more extensive disease. Local oral mucosal trauma in relation to systemic disease can arise as a consequence 
of physical (e.g. movement disorders (1) or chemical causes (e.g. the now rare instances of placing acidic 




Other rare causes of traumatic ulceration could be due to reduced pain and/or touch  sensation as might occur 
in trigeminal neuropathy secondary to metastatic deposits in the mandible or less commonly maxilla, multiple 
sclerosis, connective tissue tissue disease (e.g. scleroderma), diabetes mellitus or drug therapy (e.g. with anti-
malarials and some chemotherapy regimens). In most instances of suspected traumatic ulceration there will be 
an identifiable local and/or systemic cause, the ulcers will not be causing notable tissue destruction and the 
surrounding oral mucosa will be normal in appearance.  
 
Malignancy of the mouth is typically OSCC related to lifestyle factors (tobacco, alcohol, some betal nut 
preparations and Human papillomavirus oncogenic types) (3) however rare congenital disorders such as 
dyskeratosis congenita (4) Fanconi anaemia (5) as well as the acquired diseases oral lichen planus (6) possibly 
scleroderma (7) and syphilis (8) are risk factors for the development of this malignancy. In contrast to traumatic 
ulceration OSCC does not have any identifiable local cause, may cause local destruction and have abnormal 
surrounding mucosa (e.g.speckling). Oral squamous cell carcinoma, and indeed all most malignancies of the 
mouth, may just appear plain odd.  
 
Other malignancies related to systemic disease include several types of non-Hodgkin’s lymphoma (NHL) and 
Kaposi’s sarcoma (KS).  Non-Hodgkin’s lymphoma usually presents as a mass or area of destructive ulceration 
of the pharynx, palate or gingivae sometimes being driven by a background of immunodeficiency (e.g. HIV 
disease, iatrogenic immunosuppression) (9). Some types of oral NHL are almost specific for certain situations 
(e.g. plasmablastic lymphoma tends to be associated with HIV disease (10,11)) or may arise without obvious 
underlying cause (e.g. Natural Killer T cel lymphoma (NKTCL) (12). Oral KS tends to arise on the palate and/or 
gingivae, is blue, red or purple and does not blanche with local pressure. Prior to the advent of anti-retroviral 
therapy (ART) KS was the most common oral malignancy of HIV disease but as the numbers of patients 
receiving this therapy have climbed so there has been a substantial fall in the prevalence of this oral tumour 
(13). Nevertheless oral KS can be the first clinical manifestation of unknown (and advanced) HIV disease and 
can arise in patients receiving long-term immunosuppressive therapy.  Metastatic disease generally does not 






Other rare causes of solitary ulceration of possible systemic origin include syphilis (e.g. tertiary disease), 
primary or secondary infection of Mycobacteria tuberculosis or Mycobacteria other than Tuberculosis (MOTT) 
(15,16) and  systemic mycoses (e.g. Mucormycosis, Aspergillosis, Histoplasmosis and Parracocidiodomycosis) 
(17). Solitary ulceration secondary to neutropenias are also possible, although extensive ulceration might be 
more likely than single ulcers (18). 
 
Multiple ulcers  
Recurrent aphthous stomatitis is the most common cause of multiple superficial ovoid ulcers of the oral mucosa 
(19) but this is characterized by the patients being otherwise well (Figure 2). The multisystem inflammatory 
disorder Behcet’s disease (BD) gives rise to near identical oral ulcers as RAS but also comprises genital 
ulceration, uveitis, erythema nodosum and other cutaneous features as well as a plethora of other 
gastrointestinal, urogental, neural, musculoskeletal, cutaneous and vascular features (20).  The uncommon 
autoinflammatory syndrome of Periodic fever, aphthous ulceration, pharyngitis and adenitis (PFAPA) that 
usually arises in pre-pubertal children gives rise to episodes of superficial aphthous-like ulceration. Unlike RAS 
this disorder tends to spontaneously remit in the teenage years (21). Other autoinflammatory diseases (i.e. 
periodic fevers) such as Familial Mediterranean Fever (FMF) may also sometimes give rise to superficial oral 
ulceration (22). 
 
Ulceration similar to RAS, but without the same periodicity, can be a feature of anaemia of almost any cause. 
An important diagnostic rule is to always investigate for anaemia as being the cause of sudden onset superficial 
ulceration in an adult who does not have a history of RAS and has no signs of common bullous disease (see 
below) (23).   
 
Several mucocutaneous disorders give rise to multiple areas of oral ulceration, lichen planus being without 
doubt the most common to do so. The ulceration of oral LP (OLP) is usually bilateral, has a background of 
different white patches and arises bilaterally on the buccal, lingual and/or gingival surfaces. Up to 40% of 
patients with OLP will also have cutaneous or other mucosal features of LP (24,25).  Lichen planus usually 
arises without identifiable cause although may rarely be secondary to medication (e.g. β blockers, 




spectrum of other agents) - when disease is termed lichenoid drug reaction (LDR)) or be a manifestation of graft 
versus host disease (GvHD) (24). Associations between LP and HCV disease are tenuous. Regardless of any 
association with systemic disorders or therapy OLP-like disease is considered potentially malignant, this cancer 
risk being independent of known causative factors of OSCC or therapy of OLP (6). Lupus disease (e.g. discoid 
and systemic) may give rise to oral mucosal and/or gingival features similar to those of OLP, although lesions of 
lupus may not be bilateral and may be more likely to affect the palate than OLP. “Sun-ray” pattern lesions that 
comprise a central area of erosion or ulceration from which white linear areas radiate have been described on 
the oral mucosa of patients with lupus disease (26,27).   
 
The pemphigoid group of immunobullous disorders can give rise to bullae and/or ulceration of the palatal, 
buccal or lingual surfaces (28). Desquamative gingivitis is common (29).  Intact blood or fluid filled bullae may 
be observed in patients with pemphigoid disease as the immune-mediated attack is targeting antigens of the 
basement membrane zone (BMZ) (30).  Depending upon the type of pemphigoid patients may have blistering 
and/or ulceration of other mucocutaneous sites with oral involvement being most likely with mucous membrane 
pemphigoid (31). The IgA dermatoses (e.g. dermatitis herpetiformis [DH; often associated with gluten sensitive 
enteropathy] and linear IgA disease) can give rise to oral features similar to those of pemphigoid (32-35). 
Dapsone, often employed for the treatment of DH (and sometimes for pemphigoid) may rarely cause blue 
discolouration of the tongue secondary to methaemoglobinaemia.  
 
The pemphigus group, in particular pemphigus vulgaris (PV), characterized by the generation of a series of anti-
epithelial antibodies give rise to highly superficial ragged-bordered ulcers of the palatal, lingual and buccal 
mucosa  as well as desquamative gingivitis (Figure 3). The mouth is the first site of involvement of PV in about 
50% of affected individuals and without therapy perhaps 95% of patients will develop oral lesions (36,37).  
 
Of concern has been the realization that bullous disease can arise on a background of systemic malignancy, 
this group of disorders being termed Paraneoplastic pemphigus (PNP; sometimes also termed paraneoplastic 
autoimmune multi-organ syndrome  (PAMS)). About two thirds of the associated cancers are haematological 
(e.g. non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia and Castleman’s disease) although PNP has 




are usually the first sites of involvement although the conjunctivae and genitals may also be affected.  The oral 
features are similar to those of PV, although there can be notable labial involvement. Desquamative gingivitis 
presumably occurs. Confusingly oral lichen planus-like features can sometimes arise in PAMS.  Of concern 
PAMS can cause bronchiolitis obliterans and early death.  The variable presentation of PAMS reflects the wide 
range of autoantibodies with different epithelial targets that may be generated (38). Finally several groups of 
drugs may cause pemphigus-like disease, for example angiotensin converting enzyme (ACE) inhibitors (39).   
 
Erythema muliforme (EM) can often give rise to areas of irregular superficial ulceration of the mouth particularly 
the anterior oral mucosa.  There can also be areas of non-specific erythema, occasional vesicles or blisters or 
desquamative-like gingivitis. Target-like lesions may very rarely arise on the oral mucosa. This group of 
disorders includes EM minor, EM major, Stevens Johnson syndrome and Toxic Epidermal Necrolysis Syndrome 
(TENS) that often, but not always, are secondary to an increasingly wide range medications. The risk of EM 
type disease clearly increases with the numbers of different drugs that a patient receives -  but in some 
instances EM disease can arise in the absence of drug therapy (40). 
 
White patches 
White patches of the oral mucosa can be categorized clinically into adherent (i.e. do not easily wipe off) and 
non-adherent. The range of systemic disorders that can give rise to oral mucosal (and sometimes gingival) 
white patches is summarized in Table 2.   
 
Non-adherent white patches 
Pseudomembranous candidiasis (Thrush) is a non-adherent white or cream coloured non-adherent 
pseudomembrane that tends to arise on the posterior palate or pharynx, although when disease is severe 
almost any oral surface can be affected (Figure 4). Thrush is usually painless and typically reflects present or 
recent therapy with broad spectrum antibiotics, corticosteroids or other immunosuppressants, other  
immunodeficiencies  or long standing oral dryness (e.g. medication induced, Sjogren’s syndrome). Thrush is 
perhaps most commonly observed in patients receiving long-term corticosteroid inhaler therapy (e.g. for the 




several other types may also give rise to this clinical feature, some of which can be particularly insensitive or 
indeed resistant to antifungal therapy (41,42). 
 
Adherent white patches 
The most common causes of white patches of the mouth are local physical trauma, oral lichen planus 
(discussed above), hyperkeratosis of unknown cause, epithelial dysplasia or neoplasia. Some of these can  
arise in association with systemic disease (e.g. traumatic keratosis secondary to cerebral palsy or oral lichen 
planus due to medication) and white patches of the oral mucosa and to a lesser extent the gingivae may be a 
significant feature of systemic disease. Perhaps the most important of these is Chronic Mucocutaneous 
Candidiasis (CMC), a group of often congenitally driven disorders characterized by recurrent mucocutaneous 
candidal infection (43). In CMC the complete spectrum of presentations of oral candidal infection can occur (e.g. 
pseudomembraneous, erythematous, chronic hyperplastic).  Patients with Autoimmune Polyendocrinopathy 
Candidiasis Ectodermal Dystrophy (APECED) not only have chronic candidal infection but may have diabetes 
mellitus (which presumably will increase the risk or severity of periodontitis), enamel hypocalcification 
(secondary to hypoparathyroidism) and hypermelanotic pigmentation of the oral mucosa (secondary to 
autoimmune-driven destruction of the adrenal cortex) (44-47). Late-onset chronic mucocutaneous candidiasis 
(Good’s syndrome) is accompanied by thymoma, myasthenia gravis and bone marrow abnormalities and thus 
affected individuals may have abnormal movement of the eyes, mouth and/or face (48).   Chronic 
mucocutaneous candidiasis may be considered to be a rare risk factor for OSCC (49).   
 
There are many other potential oral mucosal manifestations of systemic disease, as summarized in Table 3. 
Perhaps the most notable of these is Addisonian pigmentation. This is actually very rare but manifests as areas 
of hypermelanotic pigmentation of the buccal mucosae. A similar appearance (together with palatal 
pigmentation) can arise with some small cell carcinomas of the lung.  
 
Salivary gland manifestations 
Disease of the salivary glands broadly manifests as local swelling and/or oral dryness (the symptom of 
xerostomia). The disorders likely to give rise to salivary gland manifestations are summarized in Tables 4 and 5. 




Salivary gland swelling(s) 
Mucoceles of the minor salivary glands of the lower lip and sialolithiasis of the submandibular gland are 
probably the most common causes of swellings salivary glands. Mucoceles have no association with systemic 
disease and ranulas, swellings of the submandibular and/or sublingual glands akin to that of mucoceles, do not 
seem to have any consistent association with systemic disease – although have been observed in patients 
receiving ART.   Sialolithiasis tends to arrive de novo but a number of systemic disorders or therapies have 
been linked to this disorder including include diabetes mellitus, hypertension and/or chronic liver disease, 
nephrolithiasis, hyperparathyroid disease and therapy with the anti-HIV agent atazanavir (50). 
 
Acute suppurative sialadenitis, that usually manifests as a painful swelling of one parotid gland is typically 
secondary to longstanding oral dryness such as Sjogren’s syndrome or radiotherapy-associated salivary gland 
disease (see below). However neonatal disease has been reported in association with prematurity, orogastric 
feeding and/or immunodeficiency. In adults links with systemic disease have included diabetes mellitus, HIV 
disease and a plethora of surgical interventions as well as the very rare coprophagia (the consumption of 
faeces). 
 
Mumps will often cause short term salivary gland swelling although hopefully the return of the high compliance 
with appropriate vaccination will lessen the frequency of this and the much more significant consequences of 
this disorder. Hepatitis C virus (HCV) infection can cause both salivary gland enlargement (typically the parotid 
glands) and reduced salivary output (see below also) and importantly there is a risk of NHL of salivary glands 
(50).  
 
Salivary gland disease associated with HIV infection tends to arise in late advanced disease although may 
rarely be the first manifestation of previously unknown HIV infection. There can be swelling and/or xerotomia, 
the former being most common in the parotid glands. Within the gland there is inflammation (sialadenitis) that is 
being driven by infection with BK polyomavirus (BKPyV) (51,52). Multicystic lymphoepithelial lesions, 
sometimes termed cystic lymphoid hyperplasia (CLH) or Benign Lymphoepithelial Lesion (BLEL) or Benign 
Lymphoepithelial cysts (BLEC), may also occur in 6% of adults and 10% of children infected with HIV. 




patients with HIV disease include intraglandular lymphadenopathy, Kaposi’s sarcoma, NHL and acute 
suppurative sialadentis. As noted above sialolithiasis possibly secondary to ART has been documented and 
some HIV protease inhibitors can cause salivary gland enlargement of unknown cause. 
 
Salivary gland swelling (often only of the submandibular glands) sometimes with xerostomia can arise in IgG4-
related disease. This is a rare fibroinflammatory disorder characterised by elevated serum levels of IgG4 and 
multi-organ inflammation (lacrimal glands, pituitary gland, thyroid, pancreas, biliary tract, lungs, prostate gland 
and retroperitoneal cavity).  The disease has predominantly been described in Asian patients (particularly from 
Japan) but affected individuals have been reported in the Western World. In the past the features were termed 
“Mikulicz’ disease” “Kuttner tumour” or “Chronic sclerosing sialadenitis”(53,54).  
 
Sialosis (sometimes termed sialoadenosis) is an uncommon non-neoplastic and non-inflammatory disorder 
possibly associated with some systemic disorders that gives rise to bilateral non-painful enlargement of the 
major salivary glands – typically the parotids. Xerostomia is not a common or dominant accompanying 
symptom. The precise cause is unknown although it may reflect a neuropathy by which unopposed sympathetic 
drive causes an increase in protein content within the acinar cells (55). This would perhaps explain the 
association of sialosis with diabetes mellitus and perhaps hypothyroidism, malnutrition, alcoholic and other 
causes of hepatic cirrhosis. Sialosis has also been observed in Bulimia nervosa, the degree of salivary gland 
enlargement possibly correlating with the frequency of bulimic symptoms and with levels of serum amylase.  
 
A wide range of drugs can cause salivary gland enlargement.  Transient and mild acute sialadenitis (sometimes 
termed “Iodide mumps”) can arise in response to iodine based contrast media (e.g. for percutaneous coronary 
interventions) (56-59). Similarly radioactive iodine, used for the treatment of thyroid cancer, can cause salivary 
gland swelling and xerostomia that may arise within 24 hours of therapy and persist for a few weeks. Other 
agents that may cause salivary gland enlargement include l-asparaginase, clozapine, phenylbutazone, 
methyldopa, interferon alpha, oxyphenbutazone, ramipril, trimethoprim/sulfamethoxazole, nicardipine, 
nifedipine, chlormethiazole, methimazole, naproxen, nitrofurantoin, sulfadiazine, captopril, cytarabine, 






The symptom of oral dryness does not always accord with loss of salivary gland function, indeed many 
individuals report some degree of usually  transient or mild oral dryness without objective evidence of reduced 
salivary gland function. Reduced salivary function gives rise to dysarthria, dysphagia, dysgeusia, some mucosal 
soreness, an increased liability to caries, gingivitis (but perhaps not periodontitis (see above)), candida  
infection (e.g. pseudomembranous, erythematous and angular chielitis), acute suppurative sialadenitis and 
reduced retention of upper full dentures. It can thus greatly lessen quality of life (50).  
 
The most common cause of persistent oral dryness  is drug therapy - with late-aged patients receiving 
polypharmacy being at greatest risk of this problem (Table 5).  Medication-related xerostomia reflects anti-
cholinergic and/or sympathomimetic actions, hence the drugs most commonly implicated in xerostomia are 
tricyclic antidepressants, benzodiazepines, atropinics, beta-blockers and anti-histamines. Morphine- derived 
agents cause oral dryness and while often promoted as having less anticholinergic actions than the tricyclics, 
the selective serotonin reuptake inhibitors (SSRI’s) still cause some dry mouth. Some other newer drug 
therapies including omeprazole, anti-HIV protease inhibitors, the nucleoside analogue HIV reverse transcriptase 
inhibitor didanosine, trospium chloride, elliptinium, and new generation antihistamines may also cause drug-
induced xerostomia.  
 
Xerostomia is the most common persistent adverse side effect of radiotherapy (RT) of the head and neck, 
affecting up to 85% of patients (61). The prevalence of RT-induced xerostomia varies with respect to RT field, 
dose, regimen, and technique. Although the introduction of Intensity modulated RT has led to a significant 
reduction in the frequency and severity of this iatrogenic problem, many patients still experience the 
consequences of irreversible salivary gland dysfunction there being a fall in salivary outflow and altered salivary 
content. (90,91).  
 
Oral dryness is a dominant symptom of Sjogren’s syndrome (Figure 5). This disorder is classified as primary 
disease in which there are symptoms and signs of ocular and oral dryness and  secondary Sjögren’s syndrome 
in which there is also a connective tissue disorder – most frequently rheumatoid arthritis or systemic lupus 




often autoimmune phenomena, while those with secondary Sjogren’s syndrome  may also have oral 
manifestations of any accompanying Connective Tissue Disease (62).  
 
The oral features of primary or secondary SS are those of oral dryness (as described previously) and salivary 
gland enlargement due to the inflammation of the actual disease, episodes of acute suppurative sialadenitis and 
NHL.  With regard to this last feature it is important to appreciate that SS is a potentially malignant disorder 
having a 4.3% risk of malignancy with a standardised incident rate of 18.9. The tumours are usually low grade 
marginal zone lymphoma (MALT), but can also be Follicle Centre, Diffuse B cell lymphoma (DBCL) or 
Lymphoplasmacytoid lymphoma (63,64).  
 
Other oral manifestations of systemic disease  
The present article has focused upon the impact of systemic disease upon the oral mucosa and salivary glands 
but a very wide range of other symptoms and/or signs of systemic disease can arise in the mouth or adjacent 
face as a consequence of disorders of non-oral structures (summarized briefly in Table 6).    
 
Conclusion 
Oral features of systemic disease can be helpful in the diagnosis and management of the underlying disorder – 
and indeed the oral symptoms may be those that most lessen the quality of life of affected individuals. The 
providers of primary oral health care have an essential role in the management of patients who may have oral 
consequences of systemic disease – as they are often likely to be the first clinicians to observe such 
abnormalities. They may not know exactly what the disease is but timely referral of patients to specialist Oral 
Medicine units will ensure that any potential oral manifestation of systemic disease is managed quickly and 
appropriately to improve the patient’s quality of life. A simple rule to perhaps apply is “It looks different thus I will 





Table 1. Systemic causes of oral mucosal or gingival ulceration 
Trauma (physical, chemical, radiation, thermal) 
 
Disorders causing aphthous-like ulceration 
Behçet disease 




Primary or recurrent herpes simplex virus infection  
Varicella-zoster virus 
Epstein-Barr virus 




Mycobacterium tuberculosis (and rarely mycobacteria other than tuberculosis (MOTT)) 
Gram-negative infections (rare) 





Mucous membrane pemphigoid (and occasionally other types) 
Pemphigus vulgaris (and occasionally other types) 
Dermatitis herpetiformis 
Linear IgA disease 
Epidermolysis bullosa acquisita 
Erythema multiforme  
 
Hematologic disorders  
Neutropenia(s) 
Non-solid haematological malignancies: Leukaemia(s) and myeloproliferative disorders 
Solid haematological malignancy: non-Hodgkin’s lymphoma 






















Table 2.  Oral mucosal white patches associated with systemic disease  
Non-adherent 
Pseudomembranous candidosis (thrush) 
Other mycoses  
Food debris 
Furred tongue 




Papillomas (warts—these are rarely of sexual origin) 
White sponge naevus 
Geographic tongue (erythema migrans – sometimes associated with type I hypersensitivity disorders or 
psoriasis) 
Frictional keratosis (e.g. as a consequence of abnormal orofacial movement) 
Lichen planus 
Lupus disorders 
Oral hairy leukoplakia 
Chronic mucocutaneous candidiasis 






Table 3. Other oral mucosal manifestations of systemic disease 
Swellings 
 
Granulomatous disease (e.g. Crohns disease; sarcoidosis) 
 Cobblestoning 
 Mucosal tags and/or nodules 
 “Stag horn” type swellings of the floor of mouth 
 Swelling of the lips and/or face (angioedema) 
Tuberous sclerosis 
Sturge Weber syndrome 




Pigmentation (usually hypermelanotic) 
 
Physiological (i.e. racially based) 





Metastatic malignant melanoma  
Hypoadrenocortical deficiency 
 Autoimmune 
 Infection of the adrenal cortex (eg. TB, CMV, others) 
Ectopic ACTH production (e.g. with some lung malignancies) 
Peutz-Jegher’s syndrome (usually per-oral rather than oral hyperpigmented areas) 
Drugs (rare, but many can do this – e.g. buspulphan, minocycline, zidovudine, others) 
 
[other types of pigmentation include central cyanosis (blue), Kaposi’s sarcoma (blue, red purple) and congenital 






Table 4.  Non-neoplastic systemic causes of salivary gland swelling 
 
Unilateral Bilateral 
Acute suppurative sialadenitis Mumps 
Recurrent parotitis of childhood HIV salivary gland disease (and related disorders) 
Sialolithiasis and other causes of ductal 
obstruction 
HCV sialadenitis 
Sjogren’s syndrome (and associated non-
Hodgkin’s lymphoma 
Sjogren’s syndrome (and rarely bilateral non-
Hodgkin’s lymphoma) 
IgG4 related disease IgG4 related disease 
Sarcoidosis Sarcoidosis 
Chronic non-specific sialadenitis Sialosis 
Xanthogranulomatous sialadenitis Pneumoparotitis 
Amyloidosis Iodine containing contrast media and radioactive 
iodine 






Table 5. Systemic causes of longstanding oral dryness 
Drugs (many) 
Radiotherapy of the head and neck 
Sjogren’s syndrome and related disorders 
Chronic graft versus host disease 
IgG4 related disease 
Sarcoidosis 
Salivary gland agenesis 
HIV salivary gland disease 
HCV sialadenitis 




Table 6.  Other oral signs and symptoms of systemic disease relevant to oral medicine  
Oral pain 
 
Any disorder that increases the risk of painful dental caries 
Dental pain secondary to sickle cell disease (very rare) 
Trigeminal neuralgia-like disease with:  
Multiple sclerosis 
Systemic lupus erythematosus 
Osteopetrosis 
Infection/tumours around the central parts of the trigeminal nerve 
Glossopharyngeal neuralgia-like disease with: 
Multiple sclerosis 
Infection/tumours around the central or peripheral parts of the glossopharyngeal nerve 
Post-herpetic neuralgia (rare in the mouth) 
Giant cell arteritis 
Migrainous disorders 
Temporomandibular disorder (TMD) –like features with: 
Ehler Danlos syndrome 
Persistent idiopathic facial pain (sometimes termed idiopathic facial pain) with: 
Others 
  
Loss of sensation (trigeminal neuropathy) 
Metastatic deposits 
Diabetes mellitus (diabetic neuropathy) 
Connective tissue disease (e.g. scleroderma, Sjogren’s syndrome, others) 
Sickle cell disease 
Familial dysautonomia 
Drugs (e.g. anti-malarials) 
Others 
 
Abnormal orofacial movement 
Facial weakness (usually unilateral) 
Upper motor nerve 
 Stroke 
 CNS malignancy 
 Others 
Lower motor nerve 
 Lyme disease (Bartonella burgdoferi) 
 Meningioma/neurofibroma/infections within the internal auditory meatus  
 Middle ear/temporal bone malignancy/destruction 
 Tumours/infection in other parts of the nerve 
 
Orofacial dyskinesias 
Trigeminal neuralgia-like disease (as above) 
Parkinson’s disease 
Tardive dyskinesia (e.g. secondary to some anti-psychotic agents). Note that metronidazole can cause tardive 
and other dyskinesias of the face) 
Rabbit syndrome (secondary to drugs) 
Chin tremor (e.g. with paroxetine) 
 
Reduced/altered tongue movement 
Bulbar palsy (i.e lower motor) – malignancy/infection/trauma of lower CNS/base of skull/tongue 
Pseudobulbar palsy (i.e upper motor) – malignancy/infection of CNS, some types of motor neurone disease 







Upper respiratory tract infection/malignancy 
Pulmonary TB, abcesses, bronchiectasis, malignancy 




End stage renal failure 
End stage hepatic failure 
Halitophobia/pseudohalitosis/olfactory reference syndrome (symptoms but no clinically detectable evidence of 






Figure 1. Oral squamous cell carcinoma – probably one of the most significant causes of solitary ulceration of 
the oral mucosa 
 
Figure 2. Recurrent aphthous stomatitis – episodic superficial oral mucosal ulceration in otherwise well children 
and adults. 
 
Figure 3. Superficial ulceration of pemphigus vulgaris – the most common type of pemphigus to affect the oral 
mucosae or gingivae 
 
Figure 4. Pseudomembranous candidiasis (thrush) of the oral mucosa 
 
Figure 5. Oral dryness secondary to Sjogren’s syndrome – this tongue is notably fissured and also has signs of 
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